logo-loader
viewOnconova Therapeutics

Onconova Therapeutics anticipates positive pivotal trial readout by the first half of 2020

Onconova Therapeutics Inc (NASDAQ:ONTX) Dr. Steven M. Fruchtman sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference in New York.

The Phase 3-stage biopharmaceutical company is focused on discovering and developing small molecule drug candidates to treat cancer, with a focus on myelodysplastic syndromes (MDS).

Quick facts: Onconova Therapeutics

Price: 0.53 USD

NASDAQ:ONTX
Market: NASDAQ
Market Cap: $73.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Co-Diagnostics expects to win a CE mark-validated...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the Utah-based company expects to achieve a CE mark validation on its coronavirus detection test from the European Union by as early as next week. Egan says the company is very enthused by the entire process of the development...

16 hours, 31 minutes ago

2 min read